Christine Zedelmayer Sells 86,012 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 86,012 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $2.80, for a total value of $240,833.60. Following the sale, the chief operating officer owned 62,586 shares of the company’s stock, valued at $175,240.80. This trade represents a 57.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The stock was sold at an average price of $2.70, for a total value of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total value of $362,438.00.

Equillium Price Performance

Equillium stock opened at $2.90 on Friday. Equillium, Inc. has a 12 month low of $0.27 and a 12 month high of $3.10. The business has a 50 day simple moving average of $2.11 and a 200-day simple moving average of $1.64. The stock has a market capitalization of $183.37 million, a PE ratio of -9.06 and a beta of 1.67.

Equillium (NASDAQ:EQ) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). As a group, equities research analysts anticipate that Equillium, Inc. will post -0.24 EPS for the current year.

Equillium News Summary

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Analyst Upgrades and Downgrades

Several research firms have issued reports on EQ. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a research report on Friday, March 27th. B. Riley Financial began coverage on Equillium in a research report on Thursday, April 16th. They issued a “buy” rating and a $6.00 price objective for the company. Wall Street Zen cut Equillium from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Raymond James Financial reiterated a “strong-buy” rating and issued a $7.00 price objective on shares of Equillium in a research report on Thursday. Finally, Roth Mkm reiterated a “buy” rating and issued a $12.00 price objective on shares of Equillium in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Equillium currently has an average rating of “Moderate Buy” and an average price target of $7.57.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP purchased a new position in Equillium in the first quarter worth $31,000. Virtu Financial LLC grew its holdings in Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after purchasing an additional 13,591 shares during the last quarter. Millennium Management LLC acquired a new stake in Equillium in the third quarter valued at $35,000. Persistent Asset Partners Ltd acquired a new stake in Equillium in the third quarter valued at $99,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Equillium in the first quarter valued at $100,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.